Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 9 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:52 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 31, 2025 | – | Mar 22, 2023 | Mar 22, 2022 |
| Operating expenses | $9.22M | $7.39M | $10.8M | $11.5M | $13.5M |
| Research and development | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M |
| Selling, general and administrative | $4.60M | $3.74M | $4.37M | $4.45M | $4.63M |
| Operating income | -$9.22M | -$7.39M | -$10.8M | -$11.5M | -$13.5M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.70M | -$7.15M | -$10.8M | -$11.5M | -$13.3M |
| EPS, basic | $-1.45 | $-9.08 | $-5.20 | $-10.10 | – |
| EPS, diluted | – | $-9.08 | $-5.20 | $-10.10 | – |
| Weighted shares, basic | 5.98M | 787.5K | 2.08M | 1.14M | – |
| Weighted shares, diluted | – | 787.5K | 2.08M | 1.14M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 31, 2025 | – | Mar 22, 2023 | Mar 22, 2022 |
| Cash and equivalents | $21.0M | $5.38M | $8.49M | $11.8M | $24.1M |
| Total current assets | $21.5M | $5.74M | $9.32M | $12.4M | $24.7M |
| Property, plant and equipment | $11.0K | $2.00K | $6.00K | $183.0K | $133.0K |
| Total assets | $21.5M | $5.74M | $9.36M | $12.8M | $25.2M |
| Accounts payable | $435.0K | $253.0K | $657.0K | $779.0K | $283.0K |
| Total current liabilities | – | $1.01M | $1.63M | $1.94M | $3.07M |
| Long-term debt | – | – | – | – | $0 |
| Total liabilities | $1.34M | $1.01M | $1.63M | $1.97M | $3.24M |
| Shareholders' equity | $20.1M | $4.72M | $7.73M | $10.8M | $21.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 31, 2025 | – | Mar 22, 2023 | Mar 22, 2022 |
| Operating cash flow | -$7.98M | -$7.11M | -$10.7M | -$12.1M | -$11.9M |
| Capital expenditures | $12.0K | $1.00K | $5.00K | $121.0K | $51.0K |
| Free cash flow | -$7.99M | -$7.11M | -$10.8M | -$12.3M | -$11.9M |
| Depreciation and amortization | $3.00K | $2.00K | $56.0K | $71.0K | $75.0K |
| Stock-based compensation | $481.0K | $147.0K | $303.0K | $414.0K | $480.0K |
| Investing cash flow | -$12.0K | $8.00K | -$5.00K | -$121.0K | -$51.0K |
| Financing cash flow | $23.6M | $4.00M | $7.41M | -$26.0K | $21.7M |
| Net change in cash | $15.6M | – | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 12.0M | +11.0% | SEC |
| Aug 4, 2026 | 11.6M | +102.9% | SEC |
| May 5, 2026 | 11.6M | +142.1% | SEC |
| Mar 2, 2026 | 11.6M | +143.1% | SEC |
| Nov 11, 2025 | 10.8M | +920.1% | SEC |
| Aug 12, 2025 | 5.73M | +565.3% | SEC |
| May 15, 2025 | 4.80M | +4.5% | SEC |
| Mar 20, 2025 | 4.78M | +4.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.